| berubicin (RTA 744) / CNS Pharma, WPD Pharma |
2019-004015-31: A phase 2 open-label study of Berubicin in adult patients with Recurrent Gliobastoma Multiforme after failure of standard first line therapy |
|
|
| Not yet recruiting | 2 | 61 | Europe | Berubicin, WP 744, Lyophilisate for solution for infusion | WPD Pharmaceuticals Sp. z o.o., WPD Pharmaceuticals Sp. z o.o. | Glioblastoma Multiforme, Glioblastoma Multiforme, Diseases [C] - Cancer [C04] | | | | |
2021-003659-40: A study of Berubicin in Adult Patients with Recurrent Glioblastoma Multiforme Un estudio de Berubicina en Pacientes Adultos con Gliobastoma Recidivante Multiforme |
|
|
| Not yet recruiting | 2 | 210 | Europe | Berubicin, WP 744, Lyophilisate for solution for infusion, Capsule, hard, Cecenu® | CNS Pharmaceuticals, Inc., CNS Pharmaceuticals, Inc. | Glioblastoma Multiforme (WHO Grade IV) Glioblastoma Multiforme (grado IV de la OMS), Glioblastoma multiforme (GBM) glioblastoma multiforme (GBM), Diseases [C] - Cancer [C04] | | | | |
NCT04762069: A Study of Berubicin in Adult Subjects With Recurrent Glioblastoma Multiforme |
|
|
| Active, not recruiting | 2 | 210 | Europe, US | Berubicin, Berubicin Hydrochloride, Lomustine, Lomustine Capsules, CCNU, CeeNU, Gleostine | CNS Pharmaceuticals, Inc., Worldwide Clinical Trials | Glioblastoma Multiforme, Adult | 12/24 | 03/25 | | |
|
|
2021-006028-41: Evaluation of the safety and efficacy of Berubicin in the treatment of central nervous system lymphomas- BERUBICIN Ocena bezpieczeństwa i skuteczności berubicyny w leczeniu chłoniaków ośrodkowego układu nerwowego- BERUBICYNA |
|
|
| Ongoing | 1/2 | 60 | Europe | Berubicin, WP 744, Lyophilisate for solution for injection | Pomorski Uniwersytet Medyczny w Szczecinie, Medical Research Agency | Primary central nervous system lymphoma (PCNSL) and secondary non-Hodgkin's lymphoma with central nervous system involvement (NHL-CNSI) Pierwotny chłoniak ośrodkowego układu nerwowego (PCNSL) i wtórny chłoniak nieziarniczy z zajęciem ośrodkowego układu nerwowego (NHL-CNSI), Primary central nervous system lymphoma and secondary non-Hodgkin's lymphoma with central nervous system involvement Pierwotny chłoniak ośrodkowego układu nerwowego i wtórny chłoniak nieziarniczy z zajęciem ośrodkowego układu nerwowego, Diseases [C] - Cancer [C04] | | | | |
NCT04915404: Berubicin in Adult Patients With Recurrent Glioblastoma Multiforme (WHO Grade IV) |
|
|
| Terminated | 1/2 | 5 | Europe | Berubicin Hydrochloride | WPD Pharmaceuticals Sp. z o.o., Worldwide Clinical Trials, National Center for Research and Development, Poland | Recurrent Glioblastoma Multiforme | 12/23 | 12/23 | | |
2019-004016-58: A Phase 1, Open-label , Dose EscalationStudy of Berubicin® in Pediatric Patientswith Progressive, Refractory, or Recurrent High GradeGliomas |
|
|
| Not yet recruiting | 1 | 35 | Europe | Berubicin, WP 744, Lyophilisate and solvent for solution for injection | WPD Pharmaceuticals Sp. z o.o., WPD Pharmaceuticals Sp. z o.o. | High Grade Gliomas, High Grade Gliomas, Diseases [C] - Cancer [C04] | | | | |
NCT05082493: A Multicenter, Study of the Safety and Pharmacokinetics of Intravenously Infused Berubicin in Pediatric Patients With Progressive, Refractory, or Recurrent High Grade Gliomas |
|
|
| Withdrawn | 1 | 35 | NA | Berubicin Hydrochloride | WPD Pharmaceuticals Sp. z o.o., Worldwide Clinical Trials | High Grade Glioma | 12/23 | 12/23 | | |
| WP1066 / Moleculin, WPD Pharma |
NCT05879250: WP1066 and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma |
|
|
| Recruiting | 2 | 39 | US | Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, Radiation Therapy, Cancer Radiotherapy, Energy Type, ENERGY_TYPE, Irradiate, Irradiated, Irradiation, Radiation, Radiation Therapy, NOS, Radiotherapeutics, Radiotherapy, RT, Therapy, Radiation, STAT3 Inhibitor WP1066, WP 1066, WP-1066, WP1066, Surgical Procedure, Operation, Surgery, Surgery Type, Surgery, NOS, Surgical, Surgical Intervention, Surgical Interventions, Surgical Procedures, Type of Surgery | Northwestern University, Moleculin Biotech, Inc., National Cancer Institute (NCI) | Glioblastoma, IDH-Wildtype, MGMT-Unmethylated Glioblastoma | 12/27 | 12/28 | | |
NCT04334863: WP1066 in Children With Refractory and Progressive or Recurrent Malignant Brain Tumors |
|
|
| Completed | 1 | 10 | US | WP1066, STAT3 Inhibitor WP1066 | Emory University, CURE Childhood Cancer, Inc., Peach Bowl LegACy Fund | Brain Tumor, Medulloblastoma, Brain Metastases | 02/23 | 02/23 | | |
| WP1122 / Moleculin, CNS Pharma, WPD Pharma |
WP1122, NCT05365321: Clinical Trial of Efficacy and Safety of Oral Drug in Adult Patients With COVID-19 |
|
|
| Not yet recruiting | 1/2 | 75 | RoW | WP1122 | Andrei Carvalho Sposito | COVID-19, Mechanical Ventilation Complication, COVID-19 Acute Respiratory Distress Syndrome | 02/23 | 10/23 | | |
| liposomal annamycin (L-ANN) / WPD Pharma, Moleculin |
NCT04887298: Study of Liposomal Annamycin for the Treatment of Subjects With Soft-Tissue Sarcomas (STS) With Pulmonary Metastases |
|
|
| Active, not recruiting | 1b/2 | 36 | US | Liposomal Annamycin (L-Annamycin) | Moleculin Biotech, Inc. | Sarcoma,Soft Tissue, Pulmonary Metastasis | 05/24 | 05/24 | | |
ANNA-SARC, NCT05518526: Phase 1b/2 Study of Liposomal Annamycin (L-Annamycin) in Subjects With Previously Treated Soft-Tissue Sarcomas (STS) With Pulmonary Metastases |
|
|
| Recruiting | 1b/2 | 64 | Europe | Liposomal Annamycin (L-Annamycin) | Maria Sklodowska-Curie National Research Institute of Oncology | Soft Tissue Sarcoma, Pulmonary Metastasis | 08/25 | 08/25 | | |
2020-005493-10: A clinical study conducted to evaluate the safety, efficacy and tolerability of a drug called liposomal annamycin administered with cytarabine, in patients with acute myeloid leukemia. |
|
|
| Not yet recruiting | 1/2 | 63 | Europe | Liposomal annamycin, [na], Lyophilisate for solution for infusion, Solution for infusion, Alexan | Moleculin Biotech, Inc., Moleculin Biotech, Inc. | Acute Myeloid Leukemia, Cancer of the myeloid line of blood cells, characterized by the rapid growth of abnormal white blood cells that build up in the bone marrow and interfere with the production of normal blood cells., Diseases [C] - Blood and lymphatic diseases [C15] | | | | |
2021-003762-13: PHASE 1B/2 STUDY OF LIPOSOMAL ANNAMYCIN (L-ANNAMYCIN) IN PATIENTS WITH PREVIOUSLY TREATED SOFT-TISSUE SARCOMAS WITH PULMONARY METASTASES (ANNA-SARC) |
|
|
| Not yet recruiting | 1/2 | 30 | Europe | L-Annamycin, CP-507, Lyophilisate for solution for infusion | Narodowy Instytut Onkologii im. Marii Skłodowskiej Curie – Państwowy Instytut Badawczy (NIO-PIB), Agencja Badan Medycznych, Moleculin Biotech | soft tissue sarcomas, soft tissue sarcomas, Diseases [C] - Cancer [C04] | | | | |
NCT05319587: Study of Liposomal Annamycin in Combination With Cytarabine for the Treatment of Subjects With Acute Myeloid Leukemia (AML) |
|
|
| Recruiting | 1/2 | 63 | Europe | Liposomal Annamycin, Cytarabine | Moleculin Biotech, Inc. | Leukemia, Myeloid, Acute | 02/24 | 04/25 | | |
| WPD101 / WPD Pharma |
| No trials found |
